Antiandrogen Monotherapy Market Growth Driven By Increasing Prevalence of Prostate Cancer in Adult Men


Antiandrogen monotherapy is one of the newest forms of prostate cancer treatment. Increasing prevalence of prostate cancer is expected to propel growth of antiandrogen monotherapy market. According to the American Cancer Society, in 2019, there will be around 174,650 men with newly diagnosed prostate cancer in the U.S., registering a 6% increase from 2018.

Antiandrogen monotherapy has revolutionized the treatment of prostate cancer as it eliminates the cause of male pattern baldness by restricting and blocking the effect of androgens on the prostate gland. It is also known as hormonal therapy, and its underlying mechanisms are similar to those of surgical removal of the testes, albeit in a very limited scope of function. By blocking the production androgen receptors, the production of DHT, the major androgen in the bloodstream, is significantly reduced. This leads to a gradual but significant reduction in the size of the prostate and its functions such as sperm production, sperm movement and male fertility. Such advantages aid in growth of the antiandrogen monotherapy market.

Increasing geriatric population is expected to aid in growth of the antiandrogen monotherapy market. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Most adult men with prostate cancer undergo an initial phase of antiandrogen monotherapy, a course of drugs that stop the production of DHT. In addition, some of these drugs reduce the activity of the enzyme 5-alpha-reductase, which is responsible for the storage and secretion of testosterone. Testosterone is an androgen, so its absence can severely affect male sexual roles. Testosterone and DHT have been shown to interact in a complex way. Not only does testosterone stimulate the growth of cancerous cells, but it also has other effects on the brain and cognition, and can exacerbate the effects of dementia. The association between testosterone and DHT is more pronounced in elderly men, but there are some reports of sexual dimorphism with antiandrogen monotherapy in young men as well. Therefore, it is possible that the sexual side effects caused by the medication could be exacerbated by antiandrogen deprivation therapy.

One phase of antiandrogen monotherapy is the use of nonsteroidal antiandrogen. These are commonly available over the counter, although some patients do not respond well to this type of treatment. It is important to note that while nonsteroidal antiandrogen relieve pain and inflammation, they are also known to cause stomach ulcers and bleeding, even though this is uncommon with castration. Therefore, whilst this form of treatment can be helpful in reducing the number of prostate cancers that are detectable during a physical examination, it may not be sufficient to prevent development in later years. Such drawbacks limit growth of antiandrogen monotherapy market.

Comments

Popular posts from this blog

U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Boston Sci Launched A New Device For Erectile Dysfunction Devices Market

Bakeable Trays Market Estimated To Develop At Cagr at 4.8% During Estimate Duration 2019-2027